• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ADMA Biologics Inc - Common Stock (NQ:ADMA)

    16.98 -0.41 (-2.39%)
    Streaming Delayed Price Updated: 12:05 PM EST, Jan 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about ADMA Biologics Inc - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
    Conference Call Scheduled for November 5, 2025, at 4:30 p.m. ET 
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
    Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET 
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
    Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET 
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
    EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    News headline image
    ADMA Biologics Statement on Tariffs
    Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain 
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
    From FN Media Group LLC
    Via GlobeNewswire
    News headline image
    ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
    Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET 
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
    Via ACCESSWIRE
    News headline image
    The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
    Via ACCESSWIRE
    News headline image
    ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation
    From Kirby McInerney LLP
    Via Business Wire
    News headline image
    ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc. (ADMA)
    From Kirby McInerney LLP
    Via Business Wire
    News headline image
    ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
    Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET 
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    News headline image
    ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    News headline image
    ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.